ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference
Get Alerts EPIX Hot Sheet
Join SI Premium – FREE
South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 2:40 p.m. Eastern Time.
David. R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings. Peter Virsik, ESSA's Chief Operating Officer, and David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
Presentation Details
Presentation Date: Thursday, March 17, 2022Presentation Time: 2:40 p.m. ET
About ESSA Pharma Inc.ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.
A webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the presentation, the webcast will be archived for 90 days.
View original content:https://www.prnewswire.com/news-releases/essa-pharma-to-present-at-oppenheimer-annual-healthcare-conference-301499623.html
SOURCE ESSA Pharma Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AG.AL Crowned Esports World Cup 2026 Club Champion After Landmark Competition in Paris
- FIA Hails Success of Landmark INDYCAR Freedom 250 Grand Prix as Motorsport Takes Centre Stage in Washington D.C.
- Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share